{
    "clinical_study": {
        "@rank": "21927", 
        "brief_summary": {
            "textblock": "OBJECTIVES:\n\n      I.  Determine the efficacy of dehydroepiandrosterone (DHEA), an androgen replacement\n      hormone, for patients with primary adrenal insufficiency (Addison's disease)."
        }, 
        "brief_title": "Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dehydroepiandrosterone Replacement for Primary Adrenal Insufficiency", 
        "condition": "Addison's Disease", 
        "condition_browse": {
            "mesh_term": [
                "Addison Disease", 
                "Adrenal Insufficiency"
            ]
        }, 
        "detailed_description": {
            "textblock": "PROTOCOL OUTLINE: This is a randomized, double-blind study.  Patients are stratified by age.\n\n      Patients are randomly assigned to androgen replacement therapy with daily\n      dehydroepiandrosterone (DHEA) or placebo for 6 months.  All patients may receive 6\n      additional months of DHEA following randomized therapy.\n\n      Women on hormonal replacement therapy may receive concurrent conjugated estrogens or oral\n      medroxyprogesterone."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "PROTOCOL ENTRY CRITERIA:\n\n        --Disease Characteristics-- Primary adrenal insufficiency (Addison's disease) Serum\n        dehydroepiandrosterone less than 0.5 nmol/L --Prior/Concurrent Therapy-- No concurrent\n        investigational drug Stable glucocorticoid/mineralocorticoid dose over past year required\n        --Patient Characteristics-- Hepatic: No hepatic disease Cardiovascular: No vascular\n        disease No thrombotic disorder No angina No elevated blood pressure on 2 readings taken 15\n        minutes apart in 1 visit, i.e.: Systolic greater than 165 mm Hg OR Diastolic greater than\n        95 mm Hg Other: No clinically significant medical abnormality No gallbladder disease No\n        malignancy No estrogen- or androgen-dependent neoplasia Benign prostatic hyperplasia\n        eligible No other endocrine disease Controlled thyroid disease with normal\n        thyroid-stimulating hormone eligible Mammogram required within 1 year prior to entry for\n        women aged 40 and over No clinically significant abnormality No undiagnosed vaginal or\n        uterine bleeding within 6 months prior to entry Pap smear required within 1 year prior to\n        entry No dysplasia (squamous intraepithelial lesion low-grade or higher)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "40", 
        "firstreceived_date": "October 18, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00004313", 
            "org_study_id": "199/11822", 
            "secondary_id": "UCSD-1062"
        }, 
        "intervention": {
            "intervention_name": "dehydroepiandrosterone", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Dehydroepiandrosterone"
        }, 
        "keyword": [
            "Addison's disease", 
            "endocrine disorders", 
            "rare disease", 
            "primary adrenal insufficiency"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "overall_official": {
            "affiliation": "University of California, Los Angeles", 
            "last_name": "Samuel S. C. Yen", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 3", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00004313"
        }, 
        "source": "Office of Rare Diseases (ORD)", 
        "sponsors": {
            "collaborator": {
                "agency": "University of California, Los Angeles", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "National Center for Research Resources (NCRR)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "August 1995", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2000"
    }, 
    "geocoordinates": {}
}